Company

Predicta Biosciences

Predicta Biosciences develops multiomics diagnostics and discovery tools for precision oncology.

About

Founded in 2023 and based in Massachusetts, US, Predicta Biosciences develops precision oncology diagnostics and therapeutic discovery tools using multiomics and AI. Its blood-based tests are designed to avoid invasive bone-marrow biopsies, and its platform combines clinical, multiomics, and immune system data. In October 2025, it raised USD 23.4 million in Series A funding led by Engine Ventures, with Lightchain Capital, Mass General Brigham Ventures, BrightEdge Ventures, Binney Street Capital, Myeloma Investment Fund, and Illumina Ventures participating.

3Funding rounds

14Investors

Sign in to see more

Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.

Sign in